PMID- 29184553
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low 
      Sensitization to Infection.
PG  - 1533
LID - 10.3389/fimmu.2017.01533 [doi]
LID - 1533
AB  - Tumor necrosis factor-alpha (TNF-alpha) blockade is an effective treatment for 
      rheumatoid arthritis (RA) and other inflammatory diseases, but in patients, it is 
      associated with reduced resistance to the infectious agents Mycobacterium 
      tuberculosis and Listeria monocytogenes, among others. Our goal was to model 
      infection and arthritis in mice and to compare etanercept, a currently used 
      anti-TNF-alpha inhibitor, to an anti-TNF-alpha vaccine. We developed a murine surrogate 
      of the TNF-alpha kinoid and produced an anti-murine TNF-alpha vaccine (TNFKi) composed of 
      keyhole limpet hemocyanin conjugated to TNF-alpha, which resulted in anti-TNF-alpha 
      antibody production in mice. We also used etanercept (a soluble receptor of TNF 
      commonly used to treat RA) as a control of TNF neutralization. In a mouse model 
      of collagen-induced arthritis, TNFKi protected against inflammation similar to 
      etanercept. In a mouse model of acute L. monocytogenes infection, all 
      TNFKi-treated mice showed cleared bacterial infection and survived, whereas 
      etanercept-treated mice showed large liver granulomas and quickly died. Moreover, 
      TNFKi mice infected with the virulent H37Rv M. tuberculosis showed resistance to 
      infection, in contrast with etanercept-treated mice or controls. Depending on the 
      TNF-alpha blockade strategy, treating arthritis with a TNF-alpha inhibitor could result 
      in a different profile of infection suceptibility. Our TNFKi vaccine allowed for 
      a better remaining host defense than did etanercept.
FAU - Belmellat, Nadia
AU  - Belmellat N
AD  - UMR 1125 INSERM, Bobigny, France.
AD  - Sorbonne Paris Cite Universite Paris 13, Bobigny, France.
FAU - Semerano, Luca
AU  - Semerano L
AD  - UMR 1125 INSERM, Bobigny, France.
AD  - Sorbonne Paris Cite Universite Paris 13, Bobigny, France.
AD  - Service de Rhumatologie, Groupe Hospitalier Avicenne-Jean Verdier-Rene Muret, 
      APHP, Bobigny, France.
FAU - Segueni, Noria
AU  - Segueni N
AD  - INEM UMR7355, CNRS, University of Orleans, Orleans, France.
FAU - Damotte, Diane
AU  - Damotte D
AD  - Service de pathologie Hopitaux Universitaires Paris Centre, APHP, Universite 
      Paris Descartes, Paris, France.
FAU - Decker, Patrice
AU  - Decker P
AD  - UMR 1125 INSERM, Bobigny, France.
AD  - Sorbonne Paris Cite Universite Paris 13, Bobigny, France.
FAU - Ryffel, Bernhard
AU  - Ryffel B
AD  - INEM UMR7355, CNRS, University of Orleans, Orleans, France.
AD  - IDM, University of Cape Town, Cape Town, South Africa.
FAU - Quesniaux, Valerie
AU  - Quesniaux V
AD  - INEM UMR7355, CNRS, University of Orleans, Orleans, France.
FAU - Boissier, Marie-Christophe
AU  - Boissier MC
AD  - UMR 1125 INSERM, Bobigny, France.
AD  - Sorbonne Paris Cite Universite Paris 13, Bobigny, France.
AD  - Service de Rhumatologie, Groupe Hospitalier Avicenne-Jean Verdier-Rene Muret, 
      APHP, Bobigny, France.
FAU - Assier, Eric
AU  - Assier E
AD  - UMR 1125 INSERM, Bobigny, France.
AD  - Sorbonne Paris Cite Universite Paris 13, Bobigny, France.
LA  - eng
PT  - Journal Article
DEP - 20171114
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5694445
OTO - NOTNLM
OT  - host-defense
OT  - infection
OT  - rheumatoid arthritis
OT  - tumor necrosis factor
OT  - vaccine
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:01
PMCR- 2017/01/01
CRDT- 2017/11/30 06:00
PHST- 2017/08/01 00:00 [received]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2017/11/30 06:00 [entrez]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.01533 [doi]
PST - epublish
SO  - Front Immunol. 2017 Nov 14;8:1533. doi: 10.3389/fimmu.2017.01533. eCollection 
      2017.